By Fineline Cube 
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong Kong Stock Exchange through an initial public offering (IPO), raising approximately HK$1.22 billion (US$156 million) with a global offering of 58,054,400 H shares at HKD21.0 per share. The company focuses on the discovery, development, and commercialization of bi-/multi-specific peptide drugs for metabolic diseases and cardiovascular and cerebrovascular disorders.
IPO Details
| Parameter | Value |
|---|---|
| Exchange | Hong Kong Stock Exchange (HKG) |
| Ticker Symbol | 2355 |
| Shares Offered | 58,054,400 H shares |
| Offering Price | HKD21.0 per share |
| Gross Proceeds | HK$1.22 billion (approximately US$156 million) |
| Listing Date | June 15, 2026 |
Company Profile & Pipeline
- Focus Area: Bi-/multi-specific peptide therapeutics
- Therapeutic Indications: Metabolic diseases, cardiovascular disorders, cerebrovascular disorders
- Pipeline Composition: One core product + six additional drug candidates
- Development Stage: Core product in Phase III clinical development
- Technology Platform: Proprietary peptide engineering and multi-receptor targeting capabilities
Core Product – MT1013
| Attribute | Detail |
|---|---|
| Molecule Type | Dual-receptor agonist peptide |
| Targets | Calcium-sensing receptor (CaSR) and Osteoglycin (OGP) receptors |
| Primary Indication | Secondary hyperparathyroidism in chronic kidney disease (CKD-SHPT) |
| Development Stage | Phase III |
| Additional Indications | CKD-mineral and bone disorder (CKD-MBD) with osteoporosis, non-dialysis CKD-SHPT |
Market Opportunity Analysis
- CKD-SHPT Market: Significant unmet medical need with limited treatment options for secondary hyperparathyroidism in CKD patients
- Peptide Therapeutics: Growing interest in peptide-based approaches due to high specificity and favorable safety profiles
- Dual-Receptor Strategy: Novel mechanism addressing both calcium regulation (CaSR) and bone metabolism (OGP) simultaneously
- Geographic Focus: Initial focus on China market with potential for global expansion
Strategic Use of IPO Proceeds
- Clinical Development: Advance MT1013 through Phase III completion and regulatory submissions
- Pipeline Expansion: Fund development of six additional drug candidates across metabolic and cardiovascular indications
- Manufacturing Capacity: Invest in GMP-compliant peptide manufacturing facilities
- Commercial Infrastructure: Build sales and marketing capabilities for product launch readiness
Competitive Landscape
- CKD-SHPT Therapies: Current market dominated by calcimimetics and vitamin D analogs with limitations in efficacy and side effects
- Innovation Gap: Limited dual-targeting approaches in the CKD-MBD space
- Peptide Advantage: MT1013’s dual-receptor mechanism offers potential for improved efficacy over single-target agents
- Market Position: Among the most advanced Chinese biotech companies focused specifically on peptide therapeutics
Financial Outlook & Milestones
- Regulatory Timeline: Potential NDA submission for MT1013 in 2027 pending Phase III results
- Revenue Projections: Anticipated commercial launch in 2028 assuming successful regulatory approval
- Pipeline Progression: Additional candidates expected to enter clinical trials within 12-24 months
- Global Strategy: Potential partnerships for international development and commercialization
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and market competition.-Fineline Info & Tech